Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation.

NCT03298412 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03298412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03298412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation.
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Terminated
Start date
May 23, 2018
Completion date
September 30, 2019
Enrollment
10 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk diffuse large b-cell lymphoma